In the third quarter of 2023, Precipio (NASDAQ:PRPO), a diagnostic products and services company, reported a significant increase in revenue and a reduction in cash burn, according to CEO Ilan Danieli during a recent shareholder update call. The company's revenues rose nearly 30% from the previous quarter and doubled year-over-year from Q3 of last year, reaching $4.5 million per quarter. This puts Precipio on an annualized run rate of $18 million, approaching its breakeven point.
Key takeaways from the call include:
- Precipio's cash burn dropped to around $1 million in Q3 2023, down approximately 60% from the same quarter of the previous year.
- The company's Pathology division has reached a breakeven point, ceasing to be a cash drain on the company.
- Precipio's Product division has not yet reached its target but is on track to do so with the current pipeline.
- The company's goal for 2023 was to reach cash flow breakeven and achieve financial independence, which it is on track to accomplish.
- Precipio has enough cash to reach its financial independence goal, whether it takes one or two more quarters.
CEO Ilan Danieli stated that the company's frugal mindset will continue even after reaching the breakeven point. The company has been able to reduce its cash burn by restructuring operational initiatives and generating positive margins and cash. The company's strategy to develop and sell diagnostic products has been successful, with the development cost of their new BCR-ABL assay being less than $100,000.
Looking ahead to 2024, Precipio plans to maintain financial stability, accelerate the growth of product revenues, and start developing new products. The company also plans to increase its visibility in the public markets through attendance at conferences, meetings with investors, and social media and digital marketing campaigns.
Full transcript - Transgenomi (PRPO) Q3 2023:
Operator: Welcome to the Precipio Third Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectations, forecasts, and assumptions, and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue, or the negative of these terms or other words or terms of similar meaning. Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the matters listed under risk factors in our annual report on Form 10-K for the year ended December 31, 2022, which is on file with the Securities Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward-looking statements, speak only to the date they are provided unless an earlier date is indicated, and we do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Now, let me hand the call over to Ilan Danieli, Precipio CEO. Please go ahead.
Ilan Danieli: Thank you, and good evening, and thank you for joining our Q3 2023 shareholder update call. As this will be the last shareholder call for the year, I'd like to take a few moments to recap the recent quarter's results, and even though we still have six weeks left to the end of the year, to frame this within the context of 2023. Following that, since our next shareholder call will be in April of next year, I'd like to share some thoughts about what we have lined up for 2024 and what you can expect to see. Let's begin with our Q3 results. As you saw in our filings, we grew revenues by almost 30% from the previous quarter and doubled year-over-year from Q3 of last year. This is a very meaningful jump for us in business volume and was driven both by our Pathology business as well as our Product business. At $4.5 million per quarter, this puts us on the annualized run rate of $18 million, which begins to approach our breakeven point. Additionally, our cash burn dropped to around $1 million in the quarter, down to approximately 40% of the $2.5 million, which was our cash burn in the same quarter of last year. This is an astounding -- outstanding accomplishment for our company, and it's important to emphasize that this was not a fat cutting exercise. Those who know me and our company, you know that we've always been a very lean and frugal company. This cash burn reduction was accomplished by a combination of restructuring operational initiatives that saved a lot of money, and of course, in addition to our revenue growth, we generated positive cash margins -- generated positive margins and cash. So, overall we had a good quarter and we are continuing to head in the right direction. Now, let me put this within the context of 2023. At the start of 2023, we set a very clear goal for the company to reach cash flow breakeven and achieve financial independence. Breaking this down, this would be achieved by leading three targets. First is the Pathology division reaches breakeven at a run rate of $14 million. The second is the Product division reaches a run rate of $8 million. And the third is significant reductions in our expenses. The combination of these three targets gets us to -- gets our business to cash flow breakeven. As of Q3, we have achieved two of those three targets. Our Pathology division has reached that target and is now a cash neutral division. This has significant implications for our future business, and I'll come back to that in a few minutes. But the important part is the most expensive part of our business, our pathology services operation, is no longer a cash drain on the company. The second target we achieved is a significant reduction in our expenses through the execution of various operational efficiencies as we've discussed. One example we've mentioned in the past is bringing our billing function in-house versus using an outside billing service. Depending on the revenue level and case mix, this billing and collections initiative and subsequent reduction in billing expenses yields savings of about between $50,000 to $75,000 in cash every month. This is just one initiative of many, which in combination have enabled us to significantly slash our cash burden. Since many of these are tied to revenues, the impact will continue to improve as we grow our business. While our Product division has not yet reached its targets as of Q3, the combination of achieving the two other targets has effectively reduced the company breakeven threshold for Product division from $8 million to $6 million or $1.5 million per quarter. With our current pipeline, we are well on our way to reaching that target. Perhaps the most important part of the equation is that we believe we have enough cash to get us to the target, whether -- and whether it takes one or two more quarters to get there, we have the gas in the tank to reach our goal of financial independence. Reaching financial independence and beginning to generate cash will be an exciting milestone from my vantage point, but we are well within reach of achieving that target. So, what does that mean for the company? Let's review a few things. First of all, by reaching the exciting milestone of breakeven, it doesn't mean we change our mindset from the frugal way in which we operate our business. One of the things I'm proud of -- proud about is that management and indeed the entire team treats every dollar as if it's coming out of their own pockets. That mindset has enabled us to look at our operations closely and find ways to operate in a more cash-efficient manner, generating the same and even better results while spending less cash. Now, let's talk about a few other impacts. First of all, having a pathology division that is breakeven essentially means we have achieved a significant component of our business model which is to create a cost-free R&D center. As you know, the company's strategy is to develop and sell diagnostic products that make labs better. In our industry, developing a product for laboratories typically means an expensive process of coming up with a product, finding a fully operational lab which has all the equipment and staffing to test it, which is itself is quite expensive. Perhaps the most challenging and most expensive element is to find patient samples upon which the company can test their product. If you look at our competitors, you will find R&D costs in the tens of millions of dollars to develop their products. Our incremental cost is minimal because we have a revenue-generating, now cash-neutral laboratory with all the equipment, staffing, and patient samples coming in every day, which once we're done with the clinical work, we can utilize for our product development needs. Essentially, we've developed a business model where our cost to develop a product is almost negligible. In August, we announced the release of our new breakthrough BCR-ABL assay. The development cost for this assay was less than $100,000. To the best of our knowledge, there is no other company that has developed this kind of model. And what it means is that in a relatively low budget and with tremendous flexibility, we can develop future products without the significant need of capital. Think of what this does for the potential ROI of a business where we can launch such a product like BCR-ABL with revenue potential as high as $40 million a year and with an incremental product development cost of less than $100,000. We like that business model. Second, this allows us to make small investments in sales and marketing of our products. Right now, we've relied on a combination of a direct sales effort, in addition to the distributors we work with, Thermo Fisher (NYSE:TMO) and McKesson (NYSE:MCK). We believe that with minor marketing efforts costing less than $100,000 for the entire year, we can significantly boost product awareness and generate additional product sales for our products. Up until now, we've been very limited in spending to enable us to reach this milestone of cash flow breakeven. Yet another impact is the ability to invest in our product production line. We currently control the entire supply chain and manufacturing process to ensure product availability and its quality. By purchasing various pieces of equipment over time, we can reduce our manufacturing cost and increasing margin, generating a positive ROI from those equipment purchases within less than 12 months. Having the volume to do that and the financial stability of the cash generating business changes the decision-making process for such purchases and subsequently improves our business economics. These are just a few of the impacts we will see once the company reaches cash flow breakeven. This is, of course, very exciting for our company, in particular to reach this point at such low revenue numbers. With a total available market potential for some of our products, for example, HemeScreen, at approximately $400 million a year, there is tremendous growth potential. Just imagine what this business looks like when we capture 10% of the market. Now, let's turn to a few things we have planned for 2024. Number one, financial stability. First and foremost, we are setting in place the infrastructure so that when we reach cash flow positives, we stay there. We've always maintained clear visibility and transparency within the entire organization as it relates to cash management, and we intend to keep it that way to ensure that the numbers continue to trend in the right direction. Number two, product growth. We're working on several strategies and partnerships that will significantly accelerate the growth of our products revenues. Those will include various business development and collaboration initiatives that we will -- that will get us directly in front of the right and large customers. More on that to come in the future. Number three, R&D development. In 2023, our R&D team's marching orders were to remain fully focused on HemeScreen and leave the other products on the back burner. This was done in order to focus on the full development of the HemeScreen product line, as well as to provide the proper support to our customers. Going into 2024, we're going to unleash our R&D team to begin developing some of the new products that have been parked while we got HemeScreen up and running. Keep in mind, our vision was never to be a one-product company, but rather to build out a suite of products we can sell to the same customers. Next year, we will see the start of executing of that component of our vision. And lastly, I think next year we get to tell the stories of the public market. The questions about our company's ability to execute, reach cash flow positive, and grow the product business will have largely been addressed. But the public markets don't really know us, and it's time they did. So, I myself am going to be spending significantly more time attending conferences and meeting with investors to share our story. We also plan to develop social media and digital marketing campaigns to get the story out. These are things that require relatively minimal resources, and with the right messaging, getting to the right audience, I think we can get many more ears to hear the story and many more eyes on the stock. I believe that the combination of our story of continued financial success and growth and the expansion of the audience that hears the story will create a multiplying impact for our shareholders. I'm really excited to see and share with you the results of the year-end and especially for next year as we turn the corner on delivering on Precipio's vision. I want to thank you for attending the call today, and I wish you and your families a happy Thanksgiving and a happy holiday season at the year-end. I look forward to connecting with you again in 2024. Thank you, and have a nice evening.
Operator: The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.
Q -:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.